Skip to content

US · VBIO · BIOTECHNOLOGY

Valion Bio, Inc. (VBIO) intrinsic value and stock valuation

$0.48as of 2026-11-21 · Mkt cap 936.29K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Valion Bio, Inc. DCF and intrinsic value

InvestorsCraft values VBIO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VBIO’s statements →

Valion Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Antonio, TX 78205 valionbio.com

How the business is doing

Fiscal 2010–2021, USD

Revenue
$0.00
20102021
Net income
-$-880K
20102021
Free cash flow
-$-1.61M
20102021
Total equity
$860K
20102021

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2010–2021, USD
20212020201920182017
Revenue$0.00$0.00$0.00$100K$160K
Operating income-$-2.34M-$-3.69M-$-4.57M-$-4.4M-$-3.47M
Net income-$-880K-$-4.37M-$-20.14M-$-4.31M-$-5.22M
EPSd-$-17.31K-$-85.96K-$-610.3K-$-186.42K-$-384.11K
Operating cash flow-$-1.61M-$-3.59M-$-3.67M-$-2.89M-$-1.38M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-1.61M-$-3.59M-$-3.67M-$-2.89M-$-1.38M
Total assets$900K$2.57M$6.08M$680K$1.18M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-880K-$-2.39M-$-5.98M-$-660K-$-1.15M
Total equity$860K$1.28M$5.02M$320K$370K
Cash and short-term investments$880K$2.39M$5.98M$660K$1.15M
Income statement
20212020201920182017
Revenue$0.00$0.00$0.00$100K$160K
Cost of revenue$0.00$0.00$0.00$80K$110K
Gross profit$0.00$0.00$0.00$20K$60K
Research and development expenses$410K$1.01M$1.74M$1.9M$890K
Selling, general and administrative expenses$1.93M$2.68M$2.82M$2.52M$2.63M
Other expenses$0.00$0.00$1.37M-$0.00-$0.00
Operating expenses$2.34M$3.69M$5.94M$4.42M$3.53M
Cost and expenses$2.34M$3.69M$4.57M$4.5M$3.63M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$10K$0.00$0.00
Depreciation and amortization$1.46M$0.00$10K$90K$0.00
Ebitda-$-880K-$-3.69M-$-4.43M-$-4.31M-$-5.22M
Operating income-$-2.34M-$-3.69M-$-4.57M-$-4.4M-$-3.47M
Total other income/expenses, net$1.46M$60K$120K$90K-$-1.75M
Income before tax-$-880K-$-3.63M-$-4.45M-$-4.31M-$-5.22M
Income tax expense$0.00$730K$120K$0.00$0.00
Net income-$-880K-$-4.37M-$-20.14M-$-4.31M-$-5.22M
Weighted average shares outstanding$50.8M$50.8M$33M$23.1M$13.6M
Weighted average diluted shares outstanding$50.8M$50.8M$33M$23.1M$13.6M
Balance sheet
20212020201920182017
Cash and short-term investments$880K$2.39M$5.98M$660K$1.15M
Net receivables$0.00$0.00$20K$10K$20K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$890K$2.41M$6.05M$680K$1.18M
Property, plant and equipment, net$0.00$120K$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$10K$160K$20K$0.00$0.00
Total assets$900K$2.57M$6.08M$680K$1.18M
Accounts payable$0.00$860K$10K$0.00$0.00
Short-term debt$0.00$130K$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$30K$1.28M$1.05M$350K$800K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$30K$1.28M$1.05M$350K$800K
Common stock$50K$50K$50K$20K$20K
Retained earnings-$-47.43M-$-46.55M-$-42.18M-$-22.04M-$-17.74M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$860K$1.28M$5.02M$320K$370K
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-880K-$-2.39M-$-5.98M-$-660K-$-1.15M
Cash flow statement
20212020201920182017
Net income-$-880K-$-4.37M-$-20.14M-$-4.31M-$-5.22M
Depreciation and amortization$0.00$0.00$10K$0.00$0.00
Stock-based compensation$0.00$0.00$350K$420K$0.00
Change in working capital-$-300K$60K$540K-$-360K$330K
Accounts receivable$0.00$0.00$0.00$10K$10K
Inventory$0.00$0.00-$-50K-$0.00$10K
Accounts payable-$-220K$220K$290K-$-210K$0.00
Net cash provided by operating activities-$-1.61M-$-3.59M-$-3.67M-$-2.89M-$-1.38M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$140K$0.00$0.00
Net cash used for investing activities$0.00$0.00$140K$0.00$0.00
Common stock issued$0.00$0.00$8.85M$2.39M$1.67M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$100K$0.00$8.85M$2.39M$2.44M
Net change in cash-$-1.51M-$-3.59M$5.33M-$-500K$1.06M
Cash at end of period$880K$2.39M$5.98M$660K$1.15M
Operating cash flow-$-1.61M-$-3.59M-$-3.67M-$-2.89M-$-1.38M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-1.61M-$-3.59M-$-3.67M-$-2.89M-$-1.38M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Valion Bio, Inc.

        Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

        CEO
        Michael R. Cavanaugh
        Employees
        52
        Beta
        1.83

        Explore

        Frequently asked questions

        What is the intrinsic value of Valion Bio, Inc. (VBIO)?

        InvestorsCraft does not currently publish an intrinsic value for VBIO. How the IC value is calculated.

        Is VBIO undervalued?

        InvestorsCraft does not publish an undervaluation signal for VBIO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.